epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small molecule drug discovery. Herein, a series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing pyridazinone derivatives were designed, synthesized and evaluated for their enzymatic inhibitory activity against c-Met kinase and cellular potency against A549, HepG2, and MCF-7 cell lines
受体
酪氨酸激酶间质上皮转化因子(MET)的失调已牵涉到几种人类癌症,是小分子药物发现的有吸引力的目标。在此,设计,合成并评估了一系列带有
哒嗪酮衍
生物的6,7-二取代-4-苯氧基
喹啉衍
生物,并评估了它们对c-Met激酶的酶抑制活性以及对A549,HepG2和MCF-7
细胞系的细胞效力。它们中的八个等于对一种或多种
细胞系和酶的阳性对照Foretinib更具活性。最有前途的化合物53具有优于Foretinib的活性,后者在单数字纳摩尔
水平(IC50 = 0.6 nM)上具有出色的c-Met激酶抑制作用,而A549(IC50 = 0.003 µM),HepG2(IC50 = 0.49 µM)癌细胞具有抑制作用和MCF-7细胞(IC50 = 0.006 µM)。